Skip to main content

Advertisement

SpringerLink
Log in

Annual report of the Japanese Breast Cancer Registry for 2019

  • Special Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

This is an annual report by the Japanese Breast Cancer Society regarding the clinical data on breast cancer extracted from the National Clinical Database-Breast Cancer Registry (NCD-BCR) of Japan. Here, we present an updated summary of 98,300 breast cancer cases registered in 2019. The median age at cancer diagnosis was 61 years (interquartile range 49–72 years), and 30.6% of the breast cancer patients were premenopausal. Of the 93,840 patients without distant metastases, 14,118 (15.0%) and 42,047 (44.8%) were diagnosed with stage 0 and I disease, respectively. Breast-conserving surgery was performed in 42,080 (44.8%) patients. Regarding axillary procedures, 62,677 (66.8%) and 7371 (7.9%) patients underwent sentinel node biopsy and axillary node dissection after biopsy, respectively. Whole breast irradiation was administered to 29,795 (70.8%) of the 42,080 patients undergoing breast-conserving surgery. Chest wall irradiation was administered to 5524 (11.1%) of the 49,637 patients who underwent mastectomy. Of the 6912 clinically lymph node-negative patients who received preoperative therapy, 5250 (76.0%) and 427 (6.2%) underwent sentinel node biopsy and axillary node dissection after biopsy, respectively; however, 602 (8.7%) patients initially underwent axillary node dissection without biopsy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kubo M, Kumamaru H, Isozumi U, Miyashita M, Nagahashi M, Kadoya T, Kojima Y, Aogi K, Hayashi N, Tamura K, et al. Annual report of the Japanese Breast Cancer Society registry for 2016. Breast Cancer. 2020;27(4):511–8.

    Article  PubMed  Google Scholar 

  2. Hayashi N, Kumamaru H, Isozumi U, Aogi K, Asaga S, Iijima K, Kadoya T, Kojima Y, Kubo M, Miyashita M, et al. Annual report of the Japanese Breast Cancer Registry for 2017. Breast Cancer. 2020;27(5):803–9.

    Article  PubMed  Google Scholar 

  3. Tada K, Kumamaru H, Miyata H, Asaga S, Iijima K, Ogo E, Kadoya T, Kubo M, Kojima Y, Tanakura K, et al. Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018. Breast Cancer. 2023;30(2):157–66.

    Article  PubMed  Google Scholar 

  4. Iwamoto T, Kumamaru H, Miyata H, Tomotaki A, Niikura N, Kawai M, Anan K, Hayashi N, Masuda S, Tsugawa K, et al. Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry. Breast Cancer Res Treat. 2016;156(3):485–94.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kataoka A, Iwamoto T, Tokunaga E, Tomotaki A, Kumamaru H, Miyata H, Niikura N, Kawai M, Anan K, Hayashi N, et al. Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry. Breast Cancer Res Treat. 2016;160(1):163–72.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kawai M, Tomotaki A, Miyata H, Iwamoto T, Niikura N, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, et al. Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry. Cancer Med. 2016;5(6):1328–40.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese Breast Cancer Registry. Ann Oncol. 2016;27(3):480–7.

    Article  CAS  PubMed  Google Scholar 

  8. Kubo M, Kawai M, Kumamaru H, Miyata H, Tamura K, Yoshida M, Ogo E, Nagahashi M, Asaga S, Kojima Y, et al. A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study. Breast Cancer Res Treat. 2019;178(3):647–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Miyashita M, Niikura N, Kumamaru H, Miyata H, Iwamoto T, Kawai M, Anan K, Hayashi N, Aogi K, Ishida T, et al. Role of postmastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer patients: a study from the Japanese Breast Cancer Registry. Ann Surg Oncol. 2019;26(8):2475–85.

    Article  PubMed  Google Scholar 

  10. Hojo T, Masuda N, Iwamoto T, Niikura N, Anan K, Aogi K, Ohnishi T, Yamauchi C, Yoshida M, Kinoshita T, et al. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004–2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society. Breast Cancer. 2020;27(1):85–91.

    Article  PubMed  Google Scholar 

  11. Ogiya R, Niikura N, Kumamaru H, Takeuchi Y, Okamura T, Kinoshita T, Aogi K, Anan K, Iijima K, Ishida T, et al. Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study. Breast Cancer Res Treat. 2020;184(2):585–96.

    Article  PubMed  Google Scholar 

  12. Yamada A, Kumamaru H, Shimizu C, Taira N, Nakayama K, Miyashita M, Honma N, Miyata H, Endo I, Saji S, et al. Systemic therapy and prognosis of older patients with stage II/III breast cancer: a large-scale analysis of the Japanese Breast Cancer Registry. Eur J Cancer. 2021;154:157–66.

    Article  PubMed  Google Scholar 

  13. Aihara T, Kumamaru H, Ishitobi M, Miyashita M, Miyata H, Tamura K, Yoshida M, Ogo E, Nagahashi M, Asaga S, et al. Prognosis and effectiveness of chemotherapy for medullary breast carcinoma. Breast Cancer Res Treat. 2022;196(3):635–45.

    Article  CAS  PubMed  Google Scholar 

  14. Shimomura A, Nagahashi M, Kumamaru H, Aogi K, Asaga S, Hayashi N, Iijima K, Kadoya T, Kojima Y, Kubo M, et al. Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan. Breast Cancer. 2022;29(6):985–92.

    Article  PubMed  Google Scholar 

  15. Terada M, Miyashita M, Kumamaru H, Miyata H, Tamura K, Yoshida M, Ogo E, Nagahashi M, Asaga S, Kojima Y, et al. Surgical treatment trends and identification of primary breast tumors after surgery in occult breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry. Breast Cancer. 2022;29(4):698–708.

    Article  PubMed  Google Scholar 

  16. Yotsumoto D, Sagara Y, Kumamaru H, Niikura N, Miyata H, Kanbayashi C, Tsuda H, Yamamoto Y, Aogi K, Kubo M, et al. Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan. Breast Cancer. 2022;29(1):1–8.

    Article  PubMed  Google Scholar 

  17. Adachi Y, Asaga S, Kumamaru H, Kinugawa N, Sagara Y, Niikura N, Jinno H, Saji S, Toi M. Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry. Breast Cancer Res Treat. 2023;201(3):397–408.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank all the affiliated institutes participating in the NCD-BCR for their efforts to register the patients’ data.

Funding

This work was funded by the Registration Committee of Breast Cancer Registry and Data Science.

Author information

Authors and Affiliations

  1. Department of Breast and Endocrine Surgical Oncology, Tohoku University School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan

    Minoru Miyashita

  2. Department of Healthcare Quality Assessment, University of Tokyo, 7‑3‑1 Hongo, Bunkyo‑Ku, Tokyo, 113‑8655, Japan

    Hiraku Kumamaru & Naoko Kinukawa

  3. Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259‑1193, Japan

    Naoki Niikura

  4. Department of Breast Surgical Oncology, Social Medical Corporation Hakuaikai, Sagara Hospital, 3-28 Matsubara, Kagoshima, 892-833, Japan

    Yasuaki Sagara

  5. Department of Breast and Endocrine Surgery, Graduate School of Medicine, The University of Tokyo, 7‑3‑1 Hongo, Bunkyo‑Ku, Tokyo, 113-8655, Japan

    Takaaki Konishi

  6. Breast and Thyroid Surgery, Kawasaki Medical School Hospital, 577 Matsushima, Kurashiki City, Okayama, 701-0192, Japan

    Takayuki Iwamoto

  7. Radiation Therapy Department, Yokkaichi Municipal Hospital, Yokkaichi, Japan

    Naoko Sanuki

  8. Plastic and Reconstructive Surgery, Mitsui Memorial Hospital, 1 Kanda‑Izumicho, Chiyoda‑Ku, Tokyo, 101‑8643, Japan

    Kenta Tanakura

  9. Department of Surgery, Division of Breast and Endocrine Surgery, School of Medicine, Hyogo Medical University, 1‑1 Mukogawa, Nishinomiya, Hyogo, 663‑8501, Japan

    Masayuki Nagahashi

  10. Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan

    Naoki Hayashi

  11. Department of Diagnostic Pathology, National Cancer Center Hospital, 5‑1‑1 Tsukiji, Chuo‑Ku, Tokyo, 104‑0045, Japan

    Masayuki Yoshida

  12. School of Nursing and Rehabilitation Sciences, Showa University, 1865 Tokaichibacho, Midori-Ku, Yokohama-Shi, Kanagawa, 226-8555, Japan

    Chie Watanabe

  13. Tokyo Metropolitan Komagome Hospital, 3 Chome-18 Honkomagome, Bunkyo City, Tokyo, Japan

    Masakazu Toi

  14. Department of Medical Oncology, Fukushima Medical University, Fukushima, Japan

    Shigehira Saji

Authors
  1. Minoru Miyashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiraku Kumamaru
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoki Niikura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuaki Sagara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takaaki Konishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takayuki Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoko Sanuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kenta Tanakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masayuki Nagahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Naoki Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masayuki Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Chie Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Naoko Kinukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Masakazu Toi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Shigehira Saji
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study concept and design: MM, NN, YS, and TK. Assembly of data: HK, NK and MM. Manuscript writing: MM. Critical revision of the manuscript for important intellectual content: The Committee of Breast Cancer Registry and Data Science of the JBCS (NN, YS, TK, TI, NS, KT, MN, NH, MY, CW, HK) and NK. Final approval of manuscript: SS and MT.

Corresponding author

Correspondence to Minoru Miyashita.

Ethics declarations

Conflict of interest

MM, HK, NN, MN, NH, MT and SS have received honorariums as speakers or consultant/advisory roles from Chugai Pharmaceutical Co., MM, NN, MN, NH, MT and SS from AstraZeneca, MM, NN, MN, NH, MT and SS from Eli Lilly, MM, NN, MN, NH, MT and SS from Pfizer Co. Ltd. MM, NN, MN, MT and SS from MSD, MM, MN, NH, MT and SS from Taiho, MM, NN, MN, NH, MT and SS from Daiichi Sankyo, MM, MN, NH, MT and SS from Eisai, MN, NH, MT and SS from Novartis, MN, MT and SS from Kyowa-Kirin, MN from Myriad genetics and Denka, NH, MT from Exact Science, MT from Devicore Medical Japan, Yakult, Sysmex, Takeda, Shimadzu and Nippon Kayaku, SS from Takeda, Ono and Nippon Kayaku. HK reports receiving consultation fee from EPS Corporation. HK and NK are affiliated with the Department of Healthcare Quality Assessment at the University of Tokyo, a social collaboration department supported by the National Clinical Database, Johnson & Johnson K.K., Nipro corporation, and Intuitive Surgical Sàrl. NN has grants or contracts from Chugai Pharmaceutical Co., Pfizer, Eisai, Mochida, Daiichi Sankyo and Novartis. TK has grants outside the submitted work from Pfizer Co. Ltd, Kanzawa Medical Research Foundation and Japan Kampo Medicines Manufacturers Association. MT has grants or contracts from Chugai Pharmaceutical Co., Pfizer, JBCRG assoc., Eisai, Daiichi Sankyo, Astellas, Yakult, AFI technology, Shionogi, Sanwa Shurui, Takeda, Taiho, KBCRN assoc., Eli Lilly, AstraZeneca, Shimadzu, Nippon Kayaku, Luxonus, GL Science and participates on a Data Safety Monitoring Board or Advisory Board of Daiichi Sankyo, Eli Lilly, BMS, Athenex Oncology, Bertis, Terumo, Kansai Medical Net. SS has grants or contracts from Chugai Pharmaceutical Co., Eisai, Daiichi Sankyo, Takeda, Taiho, Eli Lilly, AstraZeneca and participates on a Data Safety Monitoring Board or Advisory Board of Chugai/Roche, AstraZeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo and MSD.

Ethical approval

This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miyashita, M., Kumamaru, H., Niikura, N. et al. Annual report of the Japanese Breast Cancer Registry for 2019. Breast Cancer 31, 16–23 (2024). https://doi.org/10.1007/s12282-023-01526-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-023-01526-6

Keywords

Search

Navigation